|
WO2016059166A1
|
|
Humanized neuromelanin-containing rodent
|
|
WO2016046266A1
|
|
Method for predicting resistance to clopidogrel treatment
|
|
WO2015181427A1
|
|
Socs1-derived peptide for use in chronic complications relating to diabetes
|
|
EP3067116A1
|
|
Device for electrochemical detection with magnetic particles
|
|
EP3029466A1
|
|
Methods for differentiating ischemic stroke from hemorrhagic stroke
|
|
WO2016015779A1
|
|
Method to predict the lack of response to anti-tnf alpha therapies
|
|
EP2980587A1
|
|
Method to predict response to treatment with anti-TNF alpha agents
|
|
EP2887069A1
|
|
Methods for determining the propensity of a patient for hemorrhagic transformation after stroke
|
|
EP2821508A1
|
|
Primers and methods for detecting Human Hepatitis C Virus (HCV) variants in an isolated sample
|
|
EP2808031A1
|
|
Sex hormone-binding globulin for use as a medicament
|
|
US2014377763A1
|
|
Brain damage marker
|
|
EP2564197A1
|
|
A method for detecting the susceptibility to develop adverse side effects related to bioimplants
|
